from today's anns :
Imugene’s Chief Operating Officer, Leslie Chong, hails this milestone as a significant achievement in the clinical development of HER-Vaxx. "Within my experience of developing numerous world class oncology medicines it is truly remarkable to have all our sites’ Ethics Committee review applications completed and submitted within 7 weeks of finalising the study protocol. Reaching this major milestone so efficiently demonstrates the calibre of Imugene’s clinical development team and strategically places us well for a successful re-entry of Her-Vaxx into the clinic in 2016".
I am not a bio-expert but each of the previous medical anns got this extraordinary achievements compared to others mentioned. For how long will the BIO-investment world still ignore this gem ?
Time to buy more, its close to heat up I reckon.
IMU completes submission to Hospital Ethics Committees for HER-Vaxx
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |